Domainex, an integrated medicines research services partner, has purchased more than £1m of Waters equipment to enhance its capabilities in analytical chemistry, bioanalytical sciences and in vitro absorbance, distribution, metabolism and excretion (ADME) assays. The equipment will allow it to increase capacity and throughput, supporting its ongoing growth.
Two ACQUITY UPLC systems are among the purchases, as well as three mass-directed auto-purification systems (one with an SQ detector), and a highly sensitive Xevo TQ-XS triple quadrupole mass spectrometer.
The SQ detectors will enable Domainex to increase its capacity to analyse and purify compounds with higher molecular masses such as proteolysis targeting chimeras (PROTACs). The Xevo TQ-XS will allow Domainex to expand its range of in vitro ADME services to include hepatocyte stability assessments and permeability studies.
Dr Tom Mander, CEO of Domainex, said: “We have an ambitious capital investment programme planned for 2022 which we are funding from our profits. We are seeing strong demand for our range of bioanalytical chemistry services. This significant capital investment will give our analytical chemistry team access to state-of the art technologies to provide high quality data to our clients. This expansion will allow us to continue to fully support our integrated drug discovery programmes. We have used Waters equipment for many years and have always been pleased with the quality of their products and the first class support they provide us.”
Joe Kildunne, Director for Pharmaceutical Marketing at Waters, commented: “It is a pleasure to partner with Domainex, an organisation who understands the need to provide best in class scientific solutions for their sponsors. At Waters we are passionate about providing our customers with the tools and support they need to grow their scientific capabilities and their business success.’’ The purchase of the equipment follows a recent expansion for Domainex, including the opening of a facility at Unity Campus.